Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab (TEV-48125) vs Placebo for the Preventive Treatment of Episodic Migraine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms HALO-EM
- Sponsors Teva Branded Pharmaceutical Products R&D
- 26 Apr 2022 Results of pooled analysis from HALO CM, HALO EM, and FOCUS studies assessing timing and location of Injection-site adverse events with Fremanezumab in Patients With Migraine presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 26 Apr 2022 Results of pooled analysis of FOCUS and HALO studies assessing the safety and efficacy of fremanezumab in racial and ethnic subgroups presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 26 Apr 2022 Results of pooled analysis of FOCUS and HALO studies evaluating 6-month safety and efficacy of quarterly fremanezumab (QTY) and monthly fremanezumab (MLY) presented at the 74th Annual Meeting of the American Academy of Neurology 2022